SCHEMBL15051243

SCHEMBL15051243

CCOC(=O)c1cn(-c2cc(NC(C)=O)ncc2C)nc1I

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
ALOX15 P16050 3/20 0.36
NPC1 O15118 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 1/20 0.36
LMNA P02545 3/20 0.36
GALR2 O43603 1/20 0.36
MITF O75030 1/20 0.36
POLB P06746 1/20 0.36
HSP90AA1 P07900 1/20 0.36
XBP1 P17861 1/20 0.36
CCR6 P51684 1/20 0.36
TSHR P16473 1/20 0.36
P2RX7 Q99572 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15050998 0.85 L3MBTL1 (0.37) SMN1; SMN2NPC1RAB9AMAPTHSD17B10
SCHEMBL15051335 0.84 NNMT (0.39) SMN1; SMN2NPC1RAB9AL3MBTL1SYK
SCHEMBL15051168 0.75 ABL1 (0.34) SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL15072424 0.72 CRBN (0.32) L3MBTL1
SCHEMBL15051356 0.71 ALDH1A1 (0.40) ALDH1A1NPSR1KDM4EHPGDTP53
SCHEMBL23803875 0.71 NPC1 (0.40) ALDH1A1SMN1; SMN2ALOX15NPC1NPSR1
SCHEMBL30152297 0.71 NPC1 (0.40) ALDH1A1SMN1; SMN2ALOX15NPC1NPSR1
SCHEMBL15050970 0.70
SCHEMBL22717255 0.70 ALOX15 (0.52) ALDH1A1SMN1; SMN2ALOX15NPSR1KDM4E
SCHEMBL626666 0.70 KDM4E (0.39) ALDH1A1SMN1; SMN2ALOX15NPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793880-A1 HETEROARYLS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2014-10-29 EP disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
WO-2013096630-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 WO disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 ALDH1A1 2884/4885SMN1; SMN2 3783/4885ALOX15 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.